Retrospective Case Study Examining Patient Outcomes Compared to the ChemoFx Assay in Endometrial Cancer Patients

Completed

Conditions studied: Endometrial Cancer

In brief

The purpose of this study is to assess the relationship of assay sensitive patients versus assay resistant patients with progression free survival.

Key facts

Study ID

NCT01049126

Run by

Precision Therapeutics

People needed

76

Starts

2009-07-01

Expected to finish

2010-02-01

Last updated by the study team

2011-03-16

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Case has an original pathology report showing stage III, IIIa, IIIb, IIIc, IV, IVa, IVb, or recurrent endometrial cancer.
• Case includes a pathology or cytology report from initial diagnosis showing disease of one or more of the following histologic epithelial cell types: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, transitional cell carcinoma, clear cell carcinoma, or adenocarcinoma, not otherwise specified (N.O.S.).
• Case has been identified for pattern of response evaluation.
• Case must have a commercial ChemoFx drug response marker final report.

You may not qualify if…

• Cases of patients who were deceased prior to 1 cycle of chemotherapy.

Where it is running

• Precision Therapeutics, Inc. — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.